Alpine Global Management’s Agios Pharmaceuticals AGIO Stock Holding History

Alpine Global Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-46	Closed	-$5K	–	113
2015 Q2	$5K	Buy	+46	New	+$4.95K	﹤0.01%	1040

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alpine Global Management's AGIO Position: Q3 2015 in Review

Alpine Global Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2015, closing a stake of 46 shares — an estimated $5K sold.

Alpine Global Management first reported a position in AGIO in Q2 2015 and held it in 1 quarter. The position peaked at $5K in Q2 2015. 150 funds tracked by Wall St. Rank hold AGIO as of Q3 2015.

Alpine Global Management reported no remaining Agios Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Alpine Global Management sold 46 Agios Pharmaceuticals shares in Q3 2015, an estimated $5K.
Alpine Global Management first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Alpine Global Management's Agios Pharmaceuticals position peaked at $5K in Q2 2015.
150 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2015.

Based on Alpine Global Management's 13F filing for Q3 2015, filed 10 Nov 2015.